![]() | |
Clinical data | |
---|---|
Trade names | Anzupgo and Corectim, others |
Other names | JTE-052; JTE-052A |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H18N6O |
Molar mass | 310.361 g·mol−1 |
3D model (JSmol) | |
| |
|
Delgocitinib, sold under the brand name Corectim among others, is a medication used for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions. [4] Delgocitinib was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis. [4] Delgocitinib is a Janus kinase inhibitor that works by blocking activation of the JAK-STAT signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases. [5]
In the EU and the US, delgocitinib is indicated for the topical treatment of moderate to severe chronic hand eczema in adults for whom topical corticosteroids are inadequate or inappropriate. [1] [2]
In July 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Anzupgo, intended for the treatment of chronic hand eczema. [2] [6] The applicant for this medicinal product is LEO Pharma A/S. [2] Anzupgo was authorized for medical use in the European Union in September 2024. [2] [3]
Delgocitinib was approved for medical use in the United States in July 2025. [7]